Fina Lladós, general director of Amgen Iberia, explains the pending challenges of the company and its presence in the area of ​​biosimilars "because we freed up resources from the public health system that allowed us to continue adopting innovation, at the same time that we made it easier for patients to have a early access to biologic drugs that could change the course of their disease'.
An interview from 'El Global'.

READ MORE